IL132323A0 - Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors - Google Patents

Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors

Info

Publication number
IL132323A0
IL132323A0 IL13232398A IL13232398A IL132323A0 IL 132323 A0 IL132323 A0 IL 132323A0 IL 13232398 A IL13232398 A IL 13232398A IL 13232398 A IL13232398 A IL 13232398A IL 132323 A0 IL132323 A0 IL 132323A0
Authority
IL
Israel
Prior art keywords
adenovirus
tumors
treatment
intratumoral delivery
angiogenesis antagonist
Prior art date
Application number
IL13232398A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL132323A0 publication Critical patent/IL132323A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
IL13232398A 1997-04-28 1998-04-27 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors IL132323A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4498097P 1997-04-28 1997-04-28
PCT/EP1998/002491 WO1998049321A2 (en) 1997-04-28 1998-04-27 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors

Publications (1)

Publication Number Publication Date
IL132323A0 true IL132323A0 (en) 2001-03-19

Family

ID=21935358

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13232398A IL132323A0 (en) 1997-04-28 1998-04-27 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors

Country Status (14)

Country Link
US (2) US6638502B1 (zh)
EP (1) EP0979290A2 (zh)
JP (1) JP2001523103A (zh)
KR (1) KR20010020342A (zh)
CN (1) CN1177934C (zh)
AU (1) AU753781B2 (zh)
BR (1) BR9808697A (zh)
CA (1) CA2288306A1 (zh)
HU (1) HUP0002922A3 (zh)
IL (1) IL132323A0 (zh)
NO (1) NO995242L (zh)
PL (1) PL336523A1 (zh)
WO (1) WO1998049321A2 (zh)
ZA (1) ZA983553B (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
DE50015293D1 (de) * 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
WO2000068379A1 (en) * 1999-05-07 2000-11-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating tumors using antiangiogenic compounds
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
US20020115202A1 (en) * 1999-08-13 2002-08-22 Paul Hallenbeck Adenoviral vectors including dna sequences encoding angiogenic inhibitors
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
CN1183250C (zh) * 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
JP4034530B2 (ja) * 2001-02-20 2008-01-16 日本ケミカルリサーチ株式会社 抗ｈｉｖ剤
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004031381D1 (de) * 2003-12-26 2011-03-24 Nagoya Ind Science Res Inst Nagoya Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1739092A1 (en) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
US9150628B2 (en) * 2005-11-14 2015-10-06 Centre National De La Recherche Scientifique (Cnrs) PARP inhibitors
WO2007110966A1 (ja) * 2006-03-24 2007-10-04 Nihon University Ｅｓ細胞を用いた肝細胞調製法
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
CN1958075A (zh) * 2006-11-27 2007-05-09 林李家宓 含腺伴随病毒介导的抗血管生成因子的组合物及其应用
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513994A (en) * 1894-02-06 Seaming-machine for sheet-metal ware
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
AU3069189A (en) 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
FR2629818B1 (fr) 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2662440B1 (fr) 1990-05-22 1992-07-31 Rhone Poulenc Sante Procede de preparation stereoselective de derives de la phenylisoserine.
FR2662441B1 (fr) 1990-05-22 1992-10-23 Rhone Poulenc Sante Procede de preparation enantioselective de derives de la phenylisoserine.
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
MX9305855A (es) * 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
EP0711354A1 (en) 1993-07-30 1996-05-15 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
CA2187818A1 (en) 1994-04-15 1995-10-26 Robert W. Overell Gene delivery fusion proteins
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CA2188813C (en) * 1994-04-26 2010-08-03 Michael S. O'reilly Angiostatin protein, nucleic acids encoding the same and methods of detection
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
FR2736915B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants de la proteine p53 et utilisations therapeutiques
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
WO1998006437A2 (en) * 1996-08-13 1998-02-19 Chiron Corporation Compositions and methods for polynucleotide delivery

Also Published As

Publication number Publication date
HUP0002922A3 (en) 2003-03-28
WO1998049321A3 (en) 1999-02-25
CN1177934C (zh) 2004-12-01
NO995242L (no) 1999-12-27
HUP0002922A2 (hu) 2000-12-28
WO1998049321A8 (en) 1999-04-08
PL336523A1 (en) 2000-07-03
NO995242D0 (no) 1999-10-27
CN1254378A (zh) 2000-05-24
ZA983553B (en) 1999-02-04
US20040265273A1 (en) 2004-12-30
WO1998049321A2 (en) 1998-11-05
CA2288306A1 (en) 1998-11-05
BR9808697A (pt) 2000-07-11
AU753781B2 (en) 2002-10-31
US6638502B1 (en) 2003-10-28
JP2001523103A (ja) 2001-11-20
EP0979290A2 (en) 2000-02-16
AU7909698A (en) 1998-11-24
KR20010020342A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
IL132323A0 (en) Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
HUP0001964A3 (en) Multiple site delivery of adenoviral vector for the induction of angiogenesis
HK1024622A1 (en) Il 12 for the gene therapy of tumours
EG24678A (en) Combination therapy
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
ZA983543B (en) Polyethylene glycol modified interferon therapy
EP1109896A4 (en) ADENOVIRUS FORMULATIONS FOR GENE THERAPY
AU1403199A (en) Local delivery of therapeutic agents
HUP0201329A2 (en) Use of bisphosphonic acids for treating angiogenesis
ZA977745B (en) Transdermal delivery of peptides
IL127306A0 (en) Combination therapy
GB2335583B (en) Controlling delivery of radiotherapy
HUP0104046A3 (en) Adenovirus-mediated gene therapy
GB9700939D0 (en) Therapy
ZA991102B (en) Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery.
HUP9902150A3 (en) Recombinant adenoviral vectors for human tumour gene therapy
HUP0101947A3 (en) Combination for the treatment of tumors
GB0003851D0 (en) Aroma therapy delivery system
AU2193797A (en) Delivery of therapeutic agents to the prostate
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
AU2003200201A1 (en) Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of the tumors
EP1191940A4 (en) TUMORNESCROSE FACTOR RECEPTOR 5
HUP9801894A3 (en) Use of dofetilide for the preparation of pharmaceutical compositions treating congestive heart failure
MXPA02002767A (es) Usos terapeuticos del polipeptido m3.